Načítá se...
Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
BACKGROUND: Fibroblast growth factor 21 (FGF21) is an endocrine-acting hormone that has the potential to treat diabetic nephropathy. However, development of FGF21 into a therapeutic has been hindered due to its low intrinsic bio-stability. In our previous study, we have developed a recombinant human...
Uloženo v:
| Vydáno v: | BMC Biotechnol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5496364/ https://ncbi.nlm.nih.gov/pubmed/28676059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12896-017-0368-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|